Company news
Adial Pharmaceuticals, Inc news in 2025
Adial Pharmaceuticals, Inc's news releases, calls and decks from 2025, newest first.
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds
November 26, 2025
Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 14, 2025
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
October 17, 2025
Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution
October 9, 2025
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
September 16, 2025
Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
September 3, 2025
Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments
August 20, 2025
Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting
August 6, 2025
Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement
July 16, 2025
Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045
July 9, 2025
Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply
June 25, 2025
Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering
June 17, 2025
Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting
June 16, 2025
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04
June 11, 2025
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study
May 13, 2025
Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration
May 8, 2025
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds
May 2, 2025
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders
May 1, 2025
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update
March 4, 2025
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
February 25, 2025
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies
February 19, 2025
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
February 11, 2025
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
January 28, 2025
Decks in 2025
- Investor Presentation (June 2025)
Investor deck · 20 slides · June 2025
- Investor Presentation (January 2025)
Investor deck · 27 slides · Jan 13, 2025
- Investor Presentation (January 2025)
Investor deck · 20 slides · January 2025